KRAS and lung adenocarcinoma: To our knowledge, the present study is the first to investigate the impacts of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of Japanese patients with lung adenocarcinoma treated with ICIs using the C-CAT database.